Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Intellia Therapeutics (NTLA) over the last 9 years, with Dec 2024 value amounting to $47.8 million.

  • Intellia Therapeutics' Interest & Investment Income fell 44.61% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year decrease of 32.81%. This contributed to the annual value of $47.8 million for FY2024, which is 4.06% down from last year.
  • Per Intellia Therapeutics' latest filing, its Interest & Investment Income stood at $47.8 million for FY2024, which was down 4.06% from $49.8 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Interest & Investment Income high stood at $49.8 million for FY2023, and its period low was $1.3 million during FY2021.
  • Its 3-year average for Interest & Investment Income is $35.4 million, with a median of $47.8 million in 2024.
  • Per our database at Business Quant, Intellia Therapeutics' Interest & Investment Income crashed by 65.59% in 2020 and then skyrocketed by 565.78% in 2022.
  • Over the past 5 years, Intellia Therapeutics' Interest & Investment Income (Yearly) stood at $2.4 million in 2020, then plummeted by 45.45% to $1.3 million in 2021, then skyrocketed by 565.78% to $8.5 million in 2022, then soared by 483.38% to $49.8 million in 2023, then declined by 4.06% to $47.8 million in 2024.